(Ezetimibe might have some impressive protective effects against Alzheimer's.)
Researchers at the University of Arkansas for Medical Sciences (UAMS) have made a promising discovery in the fight against Alzheimer's disease and other forms of dementia. They found that ezetimibe, an FDA-approved cholesterol medication, may have the potential to halt the progression of Alzheimer's. The research team, led by Srinivas Ayyadevara, used 3-D analysis tools to identify how the drug disrupts the aggregation of tangled proteins commonly seen in Alzheimer's patients. Their findings, published in the Aging Biology journal, showed that ezetimibe prevented specific aggregate proteins from clumping together in lab-grown neurons.
The study also analyzed a clinical database of nearly 950,000 older adults and found that those taking ezetimibe had a significantly lower incidence of Alzheimer's and related forms of dementia - nearly an eightfold reduction in relative risk. While these results are promising, the researchers emphasize that further studies are needed to confirm the drug's effectiveness and safety for high-risk groups. The next step in their research is to study ezetimibe's ability to protect heart disease patients and people with mild cognitive impairment from dementia. This discovery could potentially provide an intervention for people with an increased likelihood of developing Alzheimer's due to known risk factors.


